GeneOne Life Science, Inc.

KSE 011000.KS

GeneOne Life Science, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -59.68%

GeneOne Life Science, Inc. Return on Capital Employed (ROCE) is -59.68% for the year ending December 31, 2023, a -266.94% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

GeneOne Life Science, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -16.26%, a -213.37% change year over year.
GeneOne Life Science, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -5.19%, a 70.55% change year over year.
GeneOne Life Science, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -17.62%, a 3.00% change year over year.
GeneOne Life Science, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -18.17%, a 46.46% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

KSE: 011000.KS

GeneOne Life Science, Inc.

CEO	Mr. Young-Keun Park J.D., M.B.A.
IPO Date	Feb. 4, 2000
Location	South Korea
Headquarters	The Pinnacle Gangnam
Employees	73
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years